Reading Your Prostate Treatment Plan: Questions to Ask Before Choosing Medication or Surgery

The letter arrives with the clinic’s logo and three pages of words that feel written for someone else. Grade group. Volume. Flow rate. A line near the bottom says the options are “medical management or surgical intervention,” and there is a number to call. The man reading it at his kitchen table has one question, and it is not on the page: which one?

Most people are handed prostate treatment plan questions like this at the moment they feel least able to think clearly. The plan itself is not the enemy. It is a summary of what a team believes about a gland the size of a walnut, and it almost always contains more room for discussion than its formatting suggests.

This article walks through how to read that document line by line, what the medicines and operations actually do inside the body, and which questions turn a confusing letter into a conversation you can steer.

Why reading your prostate treatment plan matters more than the appointment itself

A clinic visit is short and one-directional. The plan is the part you get to keep, reread and question. That is why treating it as a document to interrogate, rather than a verdict to accept, changes the quality of every conversation that follows.

Most plans share a structure even when the wording differs. Near the top sits the diagnosis: usually either benign prostatic hyperplasia (a non-cancerous enlargement of the prostate that squeezes the urethra, the tube that carries urine out) or prostate cancer, described by grade and stage. Below that come the measurements the team relied on. Then a list of options, sometimes with one marked as recommended, followed by a review date.

Three habits help. First, circle every term you cannot explain in a single plain sentence; each one is a question for your next call. Second, look for the word “or.” Where a plan says “medication or surgery,” the team is signaling genuine choice, and guideline bodies such as the NHS describe both routes as reasonable depending on symptom severity and preference. Third, find the review date. A plan that says “reassess in six months” is not stalling; it is telling you that time itself is part of the strategy.

Mayo Clinic notes that treatment for prostate cancer depends on how fast it is growing, whether it has spread, overall health and the balance of benefits and side effects. The same logic applies to benign enlargement. None of those variables live only in the doctor’s head. Several of them, particularly how much a symptom bothers you and how you weigh sexual and urinary side effects, live in yours. The plan cannot be complete until you have added them.

Benign enlargement or cancer: which plan are you actually holding?

The single most important line on any prostate plan is the one that says whether the problem is benign or malignant, because everything downstream, including what “medication” and “surgery” mean, depends on it.

Benign prostatic hyperplasia, often shortened to BPH, is the gradual growth of prostate tissue that most men experience with age. MedlinePlus describes it as common enough that many men over their sixties have some degree of it. It does not turn into cancer. Its treatments aim at relief: easier urination, fewer night-time trips, lower risk of the bladder failing to empty.

Prostate cancer is a different condition that can coexist with enlargement. Its treatments aim at controlling or removing malignant cells, and the trade-offs are weighed against how the cancer looks under the microscope and on imaging. The NHS lists watchful waiting, active surveillance, surgery, radiotherapy and hormone therapy among the standard approaches, with the choice shaped by stage, grade and general health.

Why does this matter for reading a plan? Because the same words carry different weight. “Surgery” for enlargement usually means removing or reshaping the inner tissue blocking the urethra while leaving the gland in place. “Surgery” for cancer usually means radical prostatectomy, the removal of the entire prostate and the seminal vesicles that sit behind it. “Medication” for enlargement means drugs that relax or shrink tissue. “Medication” for cancer generally means hormone therapy that lowers testosterone, the fuel most prostate cancers rely on.

If your plan does not state the diagnosis in plain words, or if it mentions both enlargement and a raised PSA without explaining how they relate, that ambiguity is your first question. A raised PSA has several benign causes, and the team should be able to tell you which possibility they have ruled in or out.

How prostate medications actually work inside the body

The word “medication” hides several very different mechanisms, and knowing which one your plan proposes tells you what to expect and how patient to be.

For benign enlargement, two classes dominate. Alpha blockers relax the smooth muscle fibers in the prostate and the neck of the bladder, widening the channel without changing the size of the gland. Because they act on muscle tone, the NHS notes that any improvement tends to arrive within days to a couple of weeks. Their common side effects follow from that mechanism: dizziness when standing, a drop in blood pressure, and changes in ejaculation.

The second class, 5-alpha reductase inhibitors, block the enzyme that converts testosterone into dihydrotestosterone, the more potent hormone that drives prostate growth. Over time the gland shrinks. The NHS advises that these medicines may need up to six months before any effect is noticed, which is why a plan that pairs one with a review date several months away is following the science rather than neglecting you. Reduced libido and erectile changes are the side effects people ask about most.

For prostate cancer, “medication” most often means hormone therapy, sometimes called androgen deprivation therapy. It either stops the testicles producing testosterone or blocks testosterone from reaching cancer cells. Mayo Clinic describes it as a way to slow or shrink cancer, used on its own for cancer that has spread or alongside radiotherapy for higher-risk disease confined to the gland. Hot flashes, fatigue, loss of muscle and bone density, and sexual changes are the trade-offs a plan should spell out.

None of these is a decision to make from an article. The point of understanding mechanism is to ask better questions: what is this drug trying to change, how soon should I notice, and what will you measure to decide whether it is working?

What actually happens during prostate surgery

Surgery sounds like one thing. In practice it is a family of operations with different goals, and the plan should name which one is on the table.

For benign enlargement, the reference procedure remains transurethral resection of the prostate, or TURP. A surgeon passes a thin instrument through the urethra, so there is no external cut, and removes the inner tissue pressing on the channel. Cleveland Clinic describes a hospital stay of roughly one to three days, with a catheter, a soft tube draining the bladder, for a short period afterwards. Laser techniques such as holmium laser enucleation (HoLEP) and vaporization achieve a similar clearing of the channel with less bleeding for some men. Newer minimally invasive options that lift or steam tissue exist; the NHS lists several, and their place depends on prostate size and shape.

The most common lasting effect after these operations is retrograde ejaculation, where semen flows backward into the bladder rather than out. It is harmless but changes the experience of orgasm and affects fertility. Your plan should mention it before you consent, not after.

For prostate cancer, radical prostatectomy removes the whole gland. Mayo Clinic explains it is commonly done through small abdominal incisions with robotic assistance or through a single lower abdominal incision. The urethra is rejoined to the bladder, and a catheter stays in place for a period of days to a couple of weeks while that join heals. Because the nerves controlling erections run along the prostate’s surface, the surgeon may try to spare them when the cancer’s position allows; whether that is feasible is a specific, answerable question.

Every one of these operations is done under anesthesia and carries the general risks of bleeding, infection and clots. The specific risks, urinary leakage and erectile change chief among them, are where your questions should concentrate.

Who is usually offered treatment now, and who is asked to wait

Waiting is a treatment strategy, not an absence of one. Understanding when guidelines favor it helps you read a plan that says “surveillance” without hearing “nothing.”

For benign enlargement, the NHS describes a stepped approach. Men with mild symptoms that do not trouble them are often advised to make lifestyle changes, such as reducing evening fluids, limiting caffeine and alcohol, and training the bladder, and then to check back. Medication is typically offered when symptoms are moderate or bothersome. Surgery is generally reserved for symptoms that medication has not controlled, or for complications: repeated urinary retention (being unable to pass urine), recurring infections, bladder stones, blood in the urine or signs that the kidneys are under strain.

For prostate cancer, two kinds of waiting appear on plans and they are not the same. Active surveillance is close monitoring, typically with regular PSA blood tests, MRI scans and repeat biopsies, with treatment offered if the cancer shows signs of progressing. Mayo Clinic and the NHS describe it as an option for low-risk cancers that are small, slow-growing and confined to the prostate, where immediate treatment might expose a man to side effects for little benefit.

Watchful waiting is looser. It suits men whose other health conditions or age mean aggressive treatment would be unlikely to help, and where the aim shifts to managing symptoms if they ever arise.

If your plan proposes waiting, the questions that matter are concrete: what exactly will be measured, how often, what change would trigger a different conversation, and who is responsible for calling you. If your plan proposes acting now, ask the mirror question: what makes waiting unwise in my case? A good team can answer both without hesitation.

What the numbers on your plan mean, one line at a time

Plans are dense with figures. Most fall into five groups, and each one has a plain-language meaning you are entitled to.

PSA. Prostate-specific antigen is a protein made by prostate tissue and measured in the blood. Higher levels can reflect cancer, but also enlargement, infection, recent ejaculation or vigorous exercise. The NHS notes that a raised PSA is not a diagnosis on its own. Ask how your value has changed over time; the trend often tells the team more than a single reading.

Gleason score and grade group. When a biopsy finds cancer, a pathologist grades how abnormal the cells look. Mayo Clinic explains that the two most common patterns are added to give a Gleason score, and that these are grouped into grade groups from 1 (least aggressive) to 5 (most aggressive). Grade group is the figure that most strongly shapes whether surveillance is reasonable.

Stage. This describes where the cancer is: confined to the gland, extending just beyond it, or found in lymph nodes or bone. Imaging, usually MRI and sometimes bone or PET scans, supplies it.

Prostate volume. Measured in milliliters by ultrasound or MRI, this matters most for enlargement. Larger glands respond differently to certain medicines and may steer the choice among surgical techniques.

Symptom score and flow rate. A questionnaire such as the International Prostate Symptom Score turns your experience into a number, and a flow test measures how fast urine leaves the bladder. A scan after urinating checks how much is left behind. These figures, more than PSA, drive decisions about benign enlargement.

If a number on your plan sits outside a range the team has described as expected, ask what it changes. If it changes nothing, ask why it is there.

Medication, surgery or surveillance: a side-by-side view

Tables flatten nuance, but they also make gaps visible. Use this one to spot which cells your own plan has left blank.

Question to hold against your plan	Medication	Surgery	Surveillance or watchful waiting
What is it trying to achieve?	Relieve symptoms (enlargement) or slow cancer growth (hormone therapy)	Remove the blockage (enlargement) or remove the cancer (prostatectomy)	Avoid side effects of treatment while monitoring for change
How soon might I notice a difference?	Days to weeks for alpha blockers; up to about six months for enzyme-blocking drugs (NHS)	Symptom relief after healing; catheter days to roughly two weeks depending on operation (Cleveland Clinic, Mayo Clinic)	No symptom change expected; the goal is stability
Is it reversible?	Usually, if stopped under supervision	No	Yes; treatment remains available if needed
Most-discussed side effects	Dizziness, ejaculation changes, reduced libido; hot flashes, fatigue and bone thinning with hormone therapy	Retrograde ejaculation, urinary leakage, erectile change, bleeding, infection	Anxiety of monitoring; repeat biopsies carry infection risk
What does follow-up look like?	Symptom review and, for cancer, PSA tracking	Wound and catheter checks, then PSA (cancer) or symptom scores (enlargement)	Scheduled PSA, MRI and possible biopsy at set intervals

Two observations. The reversibility row is where many men eventually place the most weight; a decision that can be revisited feels different from one that cannot. And the follow-up row is where plans most often go quiet. A plan that names an option but not the schedule for checking whether it worked is only half written. Ask for the other half before you choose.

Prostate treatment plan questions to ask before choosing medication

Medication feels like the gentler path, and often it is. It is also the path where people most frequently drift for years without a clear checkpoint. These questions build the checkpoint in from the start.

• What exactly is this medicine supposed to change? Muscle tone, gland size or hormone levels are different targets with different timelines, as the NHS describes.
• When should I expect to notice a difference, and when would you conclude it has not worked? A muscle-relaxing drug that has done nothing after several weeks and a shrinking drug that has done nothing after several months are both signals, not failures on your part.
• Which side effects are common enough that I should plan for them? Dizziness on standing, ejaculation changes and lowered libido are the ones most men raise afterwards and wish they had raised before.
• Does this drug affect my PSA reading? Some enzyme-blocking medicines lower PSA, and the team needs to interpret future results accordingly. Mayo Clinic and the NHS both flag this.
• How does this fit with my other prescriptions and my blood pressure? Bring a complete list.
• If this is hormone therapy, how will you monitor my bone health, weight and heart risk over time?
• What would make you suggest moving to surgery? Hearing the threshold now prevents the feeling later that the goalposts moved.
• Who do I call if something feels wrong between appointments?

Notice what is missing from that list: anything about doses or brands. Those are the prescriber’s responsibility, and asking them to explain their reasoning is different from asking them to defend a product. Never adjust or stop a prescribed medicine on the basis of what you read, including here; ask, and let the person who wrote the prescription decide with you.

Questions to ask before agreeing to prostate surgery

Consent is not a signature. It is the moment you can honestly say you understood the operation, its alternatives and its likely aftermath. These questions get you there.

• Which operation, specifically, and why that one for my prostate? Gland size, shape and, for cancer, tumor position all influence the choice among TURP, laser techniques, minimally invasive procedures and radical prostatectomy.
• What is the goal: relieving a blockage or removing cancer? The answer frames every other risk.
• How will you protect the nerves and muscles that control erections and continence, and how likely is that to be possible in my case? For prostatectomy, Mayo Clinic notes nerve-sparing depends on where the cancer sits.
• What will the catheter period and the first weeks look like? Ask for a typical range, not a promise.
• Which effects usually settle and which may be permanent? Retrograde ejaculation after enlargement surgery is typically lasting; some urinary leakage after prostatectomy often improves over months but not always.
• What would happen if I chose medication or surveillance instead, and for how long is that reasonable?
• Will I need further treatment afterwards, such as radiotherapy, and how would that be decided?
• Who follows me up, and how often?
• Is a second opinion something you are comfortable with? A confident team welcomes this question.

One more, often skipped: what happens to my sexual life afterwards, and who on the team helps with that? Many men find the sexual consequences of prostate treatment harder to live with than the urinary ones, and the topic is easier to open before the operation than after. A plan that includes a named route to pelvic floor or sexual health support is a plan written by people who have listened to previous patients.

What the first days and weeks usually look like

Recovery is where written plans thin out and imagination fills the gaps. Here is what mainstream sources describe as typical, remembering that individual courses vary and your team’s instructions override any general timeline.

After starting an alpha blocker, the first days may bring lightheadedness, particularly on standing quickly or in the morning. Symptom relief, if it comes, usually appears within a couple of weeks according to the NHS. After starting an enzyme-blocking drug, the honest expectation is that nothing obvious happens for months; the NHS gives up to six months as the window before effect. After starting hormone therapy, hot flashes and fatigue commonly develop over the first weeks, and the team will usually schedule PSA checks to track response.

After TURP or a laser procedure, Cleveland Clinic describes a hospital stay of about one to three days with a catheter in place for a short time. Expect blood-tinged urine, urgency and burning for a while as the raw surface heals. Most men are advised to avoid heavy lifting, straining and vigorous activity for several weeks, and to drink enough fluid to keep urine flowing.

After radical prostatectomy, Mayo Clinic notes the catheter typically remains for a period of days to around two weeks. When it is removed, some degree of urinary leakage is common; pelvic floor exercises are usually taught to help it settle over the following months. Erectile function, where nerves were spared, often recovers gradually and may take many months.

Across all of these, ask your team for three things in writing: the activity restrictions and their duration, the signs that mean “call us,” and the date of your first follow-up. A plan that answers those is a plan you can live inside.

Is there a single best plan among prostate cancer treatment options?

People type this question into search engines thousands of times a month, and the honest answer is that guidelines deliberately refuse to give one. That refusal is not evasion. It reflects the evidence.

The NHS explains that treatment for prostate cancer depends on whether the cancer is confined to the prostate, how aggressive it appears under the microscope, the man’s age and general health, and his own preferences about side effects. Mayo Clinic frames the choice the same way. For low-risk, localized cancer, active surveillance, surgery and radiotherapy are all described as reasonable options, each with a different pattern of risk: surveillance defers side effects but requires ongoing tests and tolerance of uncertainty; surgery removes the gland in one step but carries urinary and sexual consequences; radiotherapy avoids an operation but brings its own bowel, bladder and sexual effects and can be harder to follow with surgery later.

For higher-risk or more advanced disease, combinations become more common: hormone therapy alongside radiotherapy, or surgery followed by further treatment if pathology shows cancer at the edges. Cancer that has spread beyond the prostate is generally managed rather than removed, with hormone therapy at the center.

What this means for reading your plan is practical. If it names one option as “recommended,” ask what features of your cancer made the team lean that way and which alternatives they considered reasonable. If it lists several without preference, ask how other men with similar grade, stage and age tend to weigh them, and what the team has seen matter most in hindsight. Neither answer should include a percentage the team cannot source to a guideline or trial.

The best plan is the one you understand well enough to explain to someone else, and that you and your team can revisit if the facts change.

What people often get wrong about prostate treatment plans

Some misunderstandings surface again and again in clinics. Correcting them early saves worry and, occasionally, prevents a poor decision.

“A raised PSA means cancer.” It does not. The NHS lists enlargement, infection, recent ejaculation, vigorous exercise and recent procedures among the causes of a raised reading. PSA opens a conversation; MRI and biopsy answer it.

“Enlargement turns into cancer if I leave it.” Benign prostatic hyperplasia and prostate cancer are separate conditions. MedlinePlus is explicit that BPH is not cancer and does not raise the risk of it. They can coexist, which is why symptoms are still worth checking, but one does not become the other.

“Surveillance means the doctors have given up.” Active surveillance is a structured monitoring program with defined triggers for treatment, described by Mayo Clinic and the NHS as an evidence-based option for low-risk cancer. It exists because treating slow cancers immediately exposes men to side effects without a clear gain.

“Surgery for enlargement removes the whole prostate.” TURP and laser procedures remove or reshape inner tissue only. The capsule and outer gland remain, which is why PSA testing and cancer screening conversations continue afterwards.

“Medication for enlargement should work within a week or it has failed.” Alpha blockers act quickly; enzyme-blocking drugs can take months, per the NHS. The plan’s review date usually reflects which class you were given.

“Once I choose, I can’t change course.” Medication can be reviewed. Surveillance can convert to treatment. Even after surgery, further options exist. The one truly irreversible step is the operation itself, which is why the questions in this article cluster there.

“Sexual side effects are too embarrassing to raise.” They are among the most common reasons men later regret a decision. Your team has heard the question many times.

Questions to ask your care team before you decide anything

Bring this list, or your own version of it, to the appointment where the plan is discussed. Write the answers down or ask permission to record; recall after medical conversations is famously poor.

• In one sentence, what is my diagnosis, and how certain are you of it?
• Which numbers on this plan drove your recommendation, and what would have to change for you to recommend something else?
• What are all the options you consider reasonable for me, including waiting, and what are the main trade-offs of each?
• For each option, what does a typical first month look like, and what does a typical year look like?
• Which side effects usually improve, which may be permanent, and what support exists for the ones that matter most to me?
• How will we know whether the chosen approach is working, what will you measure, and when?
• If I am on medication, who reviews it and how often? If I am on surveillance, who is responsible for contacting me about results?
• Will this treatment affect other conditions I have, or medicines I take?
• Is there anything I should do or avoid before tests, such as the timing of ejaculation or exercise before a PSA sample?
• Would you be comfortable with me seeking a second opinion, and can you share my records to make that easier?
• Who is my point of contact between appointments, and how quickly should I expect a reply?

Then ask one question of yourself, ideally with someone close to you in the room: which outcome would I find hardest to live with, and does this plan take that seriously? Some men fear incontinence most, others erectile change, others the strain of repeated tests. There is no wrong answer, but there is a wrong outcome: a decision made without the answer having been heard. The treating team makes the medical judgment; you supply the values it has to serve.

When to call your doctor

Most of the decisions in this article can wait for a scheduled appointment. Some situations cannot, whether you are on medication, recovering from surgery, under surveillance or still waiting for a plan.

Seek urgent care, using emergency services if needed, if you are suddenly unable to pass urine at all, especially with a swollen, painful lower abdomen; this is acute urinary retention and the bladder needs to be drained promptly. Do the same for a fever with shaking chills after a biopsy or operation, which can signal a serious infection, or for heavy bleeding in the urine with clots that stop the flow. After surgery, a calf that becomes swollen, warm or painful, or sudden breathlessness or chest pain, can indicate a blood clot and needs immediate assessment.

Contact your care team the same day for a catheter that stops draining or leaks around its edges, burning and urgency that worsen rather than ease, new back or bone pain that does not settle, dizziness or fainting after starting a new medicine, or any side effect severe enough that you are considering stopping a prescribed drug. Do not stop it on your own; call and ask.

Arrange a non-urgent appointment if symptoms you were managing have clearly changed, if a review date on your plan has passed without contact, if you have received results you do not understand, or if you have simply changed your mind about the direction you agreed. Plans are meant to be reopened.

The NHS describes an urgent referral pathway for suspected cancer under which a specialist appointment is offered within two weeks; if you were told you are on such a pathway and have heard nothing as that window closes, call and ask where things stand. Every one of these calls is legitimate. A good team would rather hear from you once too often than once too late.

Frequently asked questions

What are the most important questions to ask a urologist about prostate treatment?

Start with what the diagnosis is and how certain the team is, then ask which numbers drove the recommendation and what alternatives, including waiting, they consider reasonable. Follow with how each option works, how soon you would notice change, which side effects usually settle and which may be permanent, how success will be measured, and who your contact is between appointments. Ask openly about sexual and urinary effects; they shape long-term satisfaction more than most men expect.

What is the 2 week rule for prostate cancer?

The “two-week rule” refers to the NHS urgent referral pathway for suspected cancer, under which a general practitioner who finds worrying signs, such as an abnormal prostate examination or a raised PSA that concerns them, refers a patient to be seen by a specialist within two weeks. It is a scheduling standard, not a statement about how fast prostate cancer grows. Being referred this way means the team wants questions answered quickly; it does not mean cancer has been confirmed.

What should you not do before a prostate exam or PSA test?

The NHS advises avoiding ejaculation and vigorous exercise for 48 hours before a PSA blood test, because both can temporarily raise the reading. You should also tell the clinician if you have a urinary infection or have had a prostate biopsy in the previous six weeks, since these can distort results. For the physical examination itself no special preparation is usually needed, though mentioning hemorrhoids, recent bowel problems or anxiety helps the clinician adjust.

Is there a best treatment plan for prostate cancer?

No single plan suits everyone, and guideline bodies deliberately avoid naming one. The NHS and Mayo Clinic describe the choice as depending on whether cancer is confined to the prostate, its grade group, the man’s age and health, and his priorities regarding side effects. For low-risk localized cancer, surveillance, surgery and radiotherapy are all considered reasonable. The most useful question is what features of your own cancer make one option more or less attractive.

Enlarged prostate: medication or surgery first?

Guidelines such as those summarized by the NHS describe a stepped approach: lifestyle changes for mild symptoms, medication when symptoms are moderate or bothersome, and surgery when medication has not helped or complications such as repeated urinary retention, infections, bladder stones or kidney strain have developed. Prostate size and how much the symptoms affect daily life both influence the choice. The sequence is a general pattern, and your urologist decides how it applies to you.

How long does prostate medication take to work?

It depends on the mechanism. Alpha blockers relax muscle in the prostate and bladder neck and, per the NHS, may improve symptoms within days to a couple of weeks. Drugs that block the enzyme driving prostate growth shrink the gland slowly and may take up to six months to show any effect. Hormone therapy for cancer is judged mainly by PSA trends over the following weeks and months rather than by symptom change.

What does active surveillance for prostate cancer involve?

Active surveillance is close monitoring rather than immediate treatment, used for low-risk cancer confined to the prostate. Mayo Clinic describes regular PSA blood tests, MRI scans and repeat biopsies at scheduled intervals, with treatment offered if results suggest the cancer is changing. It is designed to spare men the side effects of surgery or radiotherapy while cancer remains slow and small. Ask your team exactly what will be measured, how often, and what would trigger treatment.

Does prostate surgery for enlargement affect sexual function?

Often, yes, in a specific way. Procedures such as TURP and laser treatments commonly cause retrograde ejaculation, where semen flows back into the bladder at orgasm rather than out; it is harmless but changes sensation and affects fertility. Erectile function is less commonly affected by enlargement surgery than by radical prostatectomy for cancer, but it can be. Ask your surgeon how the planned technique typically affects both, and what support is available afterwards.

How long is the catheter in after prostate surgery?

It varies by operation. Cleveland Clinic describes a hospital stay of about one to three days after TURP, with the catheter usually removed within that period or shortly after. After radical prostatectomy, Mayo Clinic notes the catheter typically remains for a period of days to around two weeks while the join between bladder and urethra heals. Your surgeon sets the actual timing based on how your recovery is progressing, so treat these as typical ranges rather than promises.

Should I get a second opinion on my prostate treatment plan?

Seeking a second opinion is a normal, reasonable step before an irreversible decision such as surgery, and most teams welcome it. It is especially useful when a plan lists several options without a clear preference, when the recommended option carries side effects you find hard to accept, or when you do not fully understand the reasoning. Ask your current team to share your records, imaging and pathology so the second clinician is working from the same facts.

References

• NHS: Prostate cancer: Treatment
• NHS: Should I have a PSA test?
• NHS: Benign prostate enlargement: Treatment
• MedlinePlus: Enlarged prostate

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.